The global biosimilars market is projected to experience significant growth, with its size expected to increase from USD 34.75 billion in 2024 to approximately USD 175.79 billion by 2034. This growth is driven by factors such as the rising prevalence of cancer and the cost-effectiveness of biosimilars, which are expected to grow at a compound annual growth rate (CAGR) of 17.6% from 2025 to 2034.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5035
The biosimilars market has been experiencing notable trends as it continues to evolve and gain traction globally. Here are some of the key developments shaping the market:
Artificial Intelligence (AI) is transforming the development of biosimilars by improving the efficiency and quality of research and production processes. AI plays a crucial role in helping scientists better understand the complex structures of proteins, making it easier to develop biosimilars that are as effective as their reference biologics.
AI and machine learning (ML) algorithms can analyze the properties of biosimilars, ensuring that the drug is both safe and effective. Convolutional neural networks, for example, help monitor the physical characteristics of particles in biosimilars, ensuring consistency and quality throughout the production process.
In addition to enhancing the accuracy of biosimilar development, AI also optimizes manufacturing processes by reducing human errors and improving operational efficiency. Predictive analytics powered by AI can anticipate potential production or supply chain issues, allowing for better planning, streamlined logistics, and reduced costs.
Furthermore, AI tools like ML and deep learning can process vast amounts of data from preclinical and clinical studies, enabling faster and more accurate decision-making in the development of biosimilars. This combination of technology and research is not only accelerating biosimilar production but also making it more reliable and cost-effective.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/biosimilars-market
Access exclusive insight now @ https://www.towardshealthcare.com/price/5035
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More